FindTrial
Sign In

Premedication with pronase improves visibility during Blue Laser Imaging Endoscopy

Premedication with pronase improves visibility during Blue Laser Imaging Endoscopy in Patients with gastric precancerous

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011770
Enrollment
Unknown
Registered
2017-06-28
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

precancerous lesions of stomach

Interventions

Pronase Group:20000u pronase, 80mg simethicone and 100ml water
Control Group:80mg simethicone and 100ml water

Sponsors

The Sixth Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 40 to 75 years old male and female

Exclusion criteria

Exclusion criteria: Person with noticeable advanced gastric cancer, previous gastrectomy or partial gastric resection, on-going treatment with anticoagulant medication, antiplatelet medication or non-steroidal anti-inflammatory drugs, gastrorrhagia and the presence of hemorrhagic diseases.

Design outcomes

Primary

MeasureTime frame
influence on mucosal visualization ;Diagnosis accuracy rate;—

Secondary

MeasureTime frame
influence on examination time ;influence on flushing water volume ;—

Countries

China

Contacts

Public ContactChen Honglei

The Sixth Affiliated Hospital, Sun Yat-sen University

chl_830830@163.com+86 18138728623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026